Monotherapy with the Once Weekly Long-Acting GLP-1 Analog LY2189265 for 12 Weeks in Patients with Type 2 Diabetes: Dose-Dependent Effects on Glycemic Control in a Randomized, Double-Blind, Placebo-Controlled Study

被引：0
|
作者：
Grunberger, George
Chang, Anna
Garcia Soria, Martin Gustavo
Botros, Fady T.
Bsharat, Rebhi
Milicevic, Zvonko
机构：
来源：
DIABETES | 2011年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1094-P
引用
收藏
页码：A300 / A300
页数：1
相关论文
共 50 条
  • [31] Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study
    Nino, Antonio
    Okuda, Inaha
    Wilson, Timothy H.
    Yue, Lynn
    Nakajima, Hiromu
    Tsuboi, Maho
    Carr, Molly C.
    Seino, Yutaka
    JOURNAL OF DIABETES INVESTIGATION, 2018, 9 (03): : 558 - 566
  • [32] Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy
    McCluskey, D
    Touger, MS
    Melis, R
    Schleusener, DS
    CLINICAL THERAPEUTICS, 2004, 26 (11) : 1783 - 1790
  • [33] Effects of probiotic, cinnamon, and synbiotic supplementation on glycemic control and antioxidant status in people with type 2 diabetes; a randomized, double-blind, placebo-controlled study
    Hossein Mirmiranpour
    Hasan Fallah Huseini
    Hoda Derakhshanian
    Zohreh Khodaii
    Bahareh Tavakoli-Far
    Journal of Diabetes & Metabolic Disorders, 2020, 19 : 53 - 60
  • [34] Effects of probiotic, cinnamon, and synbiotic supplementation on glycemic control and antioxidant status in people with type 2 diabetes; a randomized, double-blind, placebo-controlled study
    Mirmiranpour, Hossein
    Huseini, Hasan Fallah
    Derakhshanian, Hoda
    Khodaii, Zohreh
    Tavakoli-Far, Bahareh
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2020, 19 (01) : 53 - 60
  • [35] Colestilan monotherapy significantly improves glycaemic control and LDL cholesterol levels in patients with type 2 diabetes: a randomized double-blind placebo-controlled study
    Kondo, K.
    Kadowaki, T.
    DIABETES OBESITY & METABOLISM, 2010, 12 (03): : 246 - 251
  • [36] Effects of Probiotics in Patients with Diabetes Mellitus Type 2: A Study Protocol for a Randomized, Double-blind, Placebo-controlled Trial
    Sabico, Shaun
    Alokail, Majed
    Al-Daghri, Nasser
    McTernan, Philip
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2016, 50 : S230 - S230
  • [37] Effects of probiotics in patients with diabetes mellitus type 2: study protocol for a randomized, double-blind, placebo-controlled trial
    Alokail, Majed S.
    Sabico, Shaun
    Al-Saleh, Yousef
    Al-Daghri, Nasser M.
    Alkharfy, Khalid M.
    Vanhoutte, Paul M.
    McTernan, Philip G.
    TRIALS, 2013, 14
  • [38] Effects of probiotics in patients with diabetes mellitus type 2: study protocol for a randomized, double-blind, placebo-controlled trial
    Majed S Alokail
    Shaun Sabico
    Yousef Al-Saleh
    Nasser M Al-Daghri
    Khalid M Alkharfy
    Paul M Vanhoutte
    Philip G McTernan
    Trials, 14
  • [39] Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, phase 3 trial
    Gao, Leili
    Bian, Fang
    Pan, Tianrong
    Jiang, Hongwei
    Feng, Bo
    Jiang, Chengxia
    Sun, Jia
    Xiao, Jianzhong
    Yan, Pangke
    Ji, Linong
    DIABETES OBESITY & METABOLISM, 2025, 27 (01): : 280 - 290
  • [40] Safety and pharmacodynamics of CJC-1134-PC, a novel GLP-1 receptor agonist, in patients with type 2 diabetes mellitus: A randomized, placebo-controlled, double-blind, dose-escalation study
    Wang, Maggie
    Kipnes, Mark
    Matheson, Stephanie
    Wen, Stella
    Lawrence, Betty
    Thibaudeau, Karen
    Castaigne, Jean-Paul
    Ulich, Thomas
    DIABETES, 2007, 56 : A133 - A133
12345